Not available
Quote | AstraZeneca PLC (NYSE:AZN)
Last: | $55.51 |
---|---|
Change Percent: | 2.47% |
Open: | $54.2 |
Close: | $55.51 |
High: | $55.84 |
Low: | $54.02 |
Volume: | 4,954,076 |
Last Trade Date Time: | 09/25/2020 04:55:24 pm |
News | AstraZeneca PLC (NYSE:AZN)
2024-03-27 07:03:30 ET Beyfortus (nirsevimab), a single-dose monoclonal antibody developed and commercialized in partnership by AstraZeneca ( NASDAQ: AZN ) and Sanofi ( NASDAQ: SNY ), has been approved in Japan for the prevention of lower respiratory tract disease (LRTD) cau...
2024-03-26 07:37:54 ET More on Viking Therapeutics Shaping The Future Of Obesity Treatment: GLP-1 Agonists At The Forefront Viking Therapeutics: Here To Stay In Obesity, Or A Flash In The Pan? Viking Therapeutics: VK2735 Data Supports A Buyout Jefferies start...
Message Board Posts | AstraZeneca PLC (NYSE:AZN)
Subject | By | Source | When |
---|---|---|---|
whytestocks: $AZN News Article - AstraZeneca PLC (NASDAQ: AZN) Records 52-Week High Friday Morning | whytestocks | investorshangout | 04/21/2023 7:30:49 PM |
whytestocks: $AZN News Article - AstraZeneca PLC (NASDAQ: AZN) Records 52-Week High Tuesday Morning | whytestocks | investorshangout | 04/18/2023 7:20:48 PM |
https://twitter.com/Prof_Oak_/status/1646929438594957312 | jondoeuk | investorshub | 04/14/2023 6:02:56 PM |
whytestocks: $AZN News Article - Fusion Pharmaceuticals Announces IND Clearance for FPI-2068, a Join | whytestocks | investorshangout | 04/12/2023 8:25:49 PM |
whytestocks: $AZN News Article - Astrazeneca Plc (NASDAQ: AZN) Highlighted for Surprising Price Acti | whytestocks | investorshangout | 04/05/2023 6:05:46 PM |
News, Short Squeeze, Breakout and More Instantly...
AstraZeneca PLC Company Name:
AZN Stock Symbol:
NYSE Market:
Wednesday, Japan approved AstraZeneca Plc (NASDAQ:AZN) and Sanofi SA’s (NASDAQ:SNY) Beyfortus (nirsevimab), a long-a...
First and only long-acting C5 complement inhibitor offers patients with AQP4 Ab+ NMOSD the potential to live relapse-free Unprecedented relapse risk reduction observed in CHAMPION-NMOSD trial underscores how ULTOMIRIS may redefine patient journey for rare neurological disease ...
Thursday, Merck & Co Inc (NYSE:MRK) released topline data from the Phase 3 KEYLYNK-006 trial evaluating Keytruda (pembrolizumab) in c...